Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

XYZAL

LEVOCETIRIZINE DIHYDROCHLORIDE

Standard Dose
2.5MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: 901 REQUIRED Marketing status: Discontinued
Summary

Approval overview XYZAL is listed in Drugs@FDA under application 022157 (NDA).

Review priority: 901 REQUIRED Marketing status: Discontinued Active ingredient LEVOCETIRIZINE DIHYDROCHLORIDE Form and strength SOLUTION;ORAL - 2.5MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor CHATTEM SANOFI Submission history Latest submission status date: 2025-07-11 00:00:00.

Structured Monograph

Clinical summary

Approval overview XYZAL is listed in Drugs@FDA under application 022157 (NDA). Review priority: 901 REQUIRED Marketing status: Discontinued Active ingredient LEVOCETIRIZINE DIHYDROCHLORIDE Form and strength SOLUTION;ORAL - 2.5MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor CHATTEM SANOFI Submission history Latest submission status date: 2025-07-11 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: 901 REQUIRED

Interaction Notes

  • No interaction notes stored yet.
XYZAL (LEVOCETIRIZINE DIHYDROCHLORIDE) | Drug Monograph | MedicHelpline